key: cord-0885323-utvzve81
authors: Manglik, Aashish; Wingler, Laura M.; Rockman, Howard A.; Lefkowitz, Robert J.
title: β-Arrestin–Biased Angiotensin II Receptor Agonists for COVID-19
date: 2020-05-15
journal: Circulation
DOI: 10.1161/circulationaha.120.048723
sha: 5d65f1e33ac03133ab67527c77cc55b9c9e1cc37
doc_id: 885323
cord_uid: utvzve81

nan

Binding of the virus to ACE2 leads to its internalization and downregulation of ACE2, 2 which disrupts RAAS homeostasis through 2 related mechanisms. First, reducing the levels of active ACE2 in the plasma membrane slows Ang II degradation, prolonging its potentially harmful effects. Second, reducing ACE2 availability lowers levels of Ang(1-7), which competes with Ang II for receptor binding and has protective cardiopulmonary properties in its own right. Ang(1-7) promotes vasodilation, decreases inflammation and fibrosis, and attenuated lung injury in an ARDS animal model. 3 Intriguingly, Ang(1-7) acts as a β-arrestin-biased ligand for the AT1R. 4 Several lines of evidence suggest that interference in RAAS homeostasis by SARS-CoV-2 infection contributes to the severe ARDS and cardiomyopathies that many patients with COVID-19 develop. Although not definitive, genetic studies have implicated inappropriate activation of the RAAS in the severity of ARDS. More directly, ACE2 activity is protective in preclinical models of acute lung injury and ARDS. 2,3 These observations have spurred clinical trials to test multiple approaches designed to modulate elevated levels of Ang II-induced signaling for COVID-19 infections, including the angiotensin receptor blocker losartan and recombinant human ACE2. However, these therapeutic approaches do not explicitly harness the beneficial β-arrestin-mediated signaling pathways promoted by Ang(1-7) itself.

We hypothesize that an AT1R ligand that blocks Ang II activation of Gq signaling, but further activates protective β-arrestin signaling, could lessen the tissue damage in the lung and heart that occurs with fulminant disease accompanying COVID-19. Although Ang(1-7) itself has poor pharmacokinetic properties, other AT1R ligands have been developed that exhibit the same βarrestin-biased pharmacological profile but are more potent, efficacious, and metabolically stable (Figure) . β-Arrestin-biased angiotensin II receptor agonists have been evaluated previously in phase IIb clinical trials for acute heart failure. Although this approach did not confer benefit over placebo, no safety issues were seen, and post hoc analyses suggested a reduced serum creatinine and trends toward improved 180-day outcomes in patients with elevated baseline systolic blood pressure. 5 The potential benefit of this approach in heart failure may therefore be specific to patients with elevated reninangiotensin signaling, a population also at significantly higher risk for adverse outcomes from COVID-19.

Drug repurposing is one of the few viable strategies to tackle the surge of acutely decompensating patients with COVID-19. It is now well established that inappropriate Ang II signaling worsens outcomes in ARDS pathophysiology, especially in the context of SARS-CoV infections. Whereas the potential of angiotensin receptor blockers to mitigate aberrant AT1R signaling in COVID-19 has received considerable attention, we

SARS-CoV-2 enters cells via angiotensin converting enzyme 2 (ACE2), leading to downregulation of ACE2 activity. Angiotensin II (Ang II) signals through the Ang II type 1 receptor (AT1R) via classic Gq signaling to drive vasoconstriction and adverse cellular responses in heart failure and acute lung injury. Ang II action is tempered by β-arrestin. Cleavage of Ang II by ACE2 both decreases Ang II levels and leads to production of Ang(1-7), an endogenous β-arrestin-biased agonist of the AT1R with potentially therapeutically beneficial effects. Compared with angiotensin receptor blockers (ARBs), synthetic biased agonists of the AT1R, which have improved potency and pharmacodynamic properties compared with Ang(1-7), may have a more favorable profile in patients with coronavirus disease 2019 (COVID-19) because they both block Ang II activity and induce β-arrestin signaling.

propose that the cellular signaling mechanisms of this receptor could be harnessed even more optimally by modulating it with biased ligands. Such precise modulation of AT1R signaling may also provide therapeutic options for future respiratory pandemics by acting on a central host signaling pathway contributing to ARDS pathophysiology, and should be explored expeditiously for its therapeutic potential for COVID-19.

Sources of Funding Funding was provided by the Searle Scholars Program (A.M.) and the National Institutes of Health (grants HL056687 and HL075443 to H.A.R., HL16037 to R

βarrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury

The renin-angiotensin system in acute respiratory distress syndrome

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Ang-(1-7) is an endogenous β-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy

Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF

TRV027 is a β-arrestin-biased angiotensin II receptor agonist developed by Trevena Inc. Dr Rockman is a scientific cofounder of and owner of stock in Trevena Inc. Dr Lefkowitz is a scientific cofounder of and owner of options in Trevena Inc. The other authors report no conflicts.